Compliance of Traditional Chinese Medicine in Young Patients With Rheumatic Diseases

Chronic Rheumatic Diseases Clinical Trial

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT02260323
• Other study ID #: CT20141003
• Status: Enrolling by invitation
• Phase: N/A
• First received: October 2, 2014
• Last updated: March 31, 2017
• Start date: October 2014
• Est. completion date: February 2022

Study information

• Verified date: March 2017
• Source: Chengdu PLA General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the compliance of traditional Chinese medicine (TCM) in young people with Chronic rheumatic disease

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 300
• Est. completion date: February 2022
• Est. primary completion date: January 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• were between 18 and 35 years of age

• without use of TCM in the previous 3 months

• and had a Steinbrocker functional status of class I, II, or III

Exclusion Criteria:

• previous general health conditions disallowed their use of TCM

• were pregnant

• lack of motivation, remote from home, time-consuming,intervention, or other personal difficulties

Related Conditions & MeSH terms

• Chronic Rheumatic Diseases
• Collagen Diseases
• Rheumatic Diseases

Intervention

Other:
• patient-tailored anti-arthritis herbs
patient use tailored anti-arthritis herbs
• patient-tailored DMARDs
patient use tailored disease-modifying antirheumatic drugs

Locations

Country	Name	City	State
China	General Hospital of Chengdu Military Area Command PLA	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
Chengdu PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes from baseline in HBCS(Hill-Bone Compliance Scale) score at 48 weeks		at 0 week, 12 weeks, 24 weeks, 48 weeks
Primary	Changes from baseline in MARS(Medication Adherence Rating Scale) score at 48 weeks		at 0 week, 12 weeks, 24 weeks, 48 weeks